Rob Scott Md Email & Phone Number

Los Angeles, CA, US

Balma, Occitanie, FR

Sepsis is one of the major medical challenges for new drug development. While Sepsis ranks third as a cause of death behind heart disease and cancer, those two diseases have been characterized by a huge amount of progress in terms of new therapies. This progress has led to steady reductions in age adjusted mortality over the last 20 years. There are no.

Zwijnaarde, BE

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with.

Copenhagen, DK

Draupnir Bio is harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD). We are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and.

Seattle, Washington, US

Having had the opportunity to successfully bring to market one therapeutic that emerged from rare genetic variants, Repatha, I am thrilled to work with the Variant Bio team and play a role in the novel science that is likely to emerge. My role was expanded this year to include both the Board and the Scientific Advisory Board and I'm looking forward to the.

OncoSpherix is the culmination of a multi-year research program to identify novel and clinically important aspects of the role of hypoxia-driven gene expression in tumor survival and spread, and to create and refine new chemical entities that target hypoxia-driven pathways.

New York, US

I am honored to work pro bono with Bioethics International (BEI) in their mission to advance patient and global public health by improving the ethics, transparency, patient-centricity, and governance of healthcare innovation and delivery. BEI focuses on the ethics and governance of how medicines, vaccines, biologics, and devices are researched, developed.

Alderley Park, Macclesfield, GB

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease. Redx's lead oncology candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2.

Waltham, Massachusetts, US

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep.

Warrington, PA, US

WindTree is a clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The lead development program, istaroxime, is a first-in-class treatment for acute heart failure and early cardiogenic shock and has Fast-Track.

North Chicago, Illinois, US

Responsible for leading AbbVie’s advancement of early and late stage development programs across a broad range of therapeutic areas (neuroscience, immunology, oncology, infectious disease, general medicine) including 10 late stage/phase 3 programs and over 20 early and mid-stage development projects.Manage an organization of over 3,300 individuals located.

Chicago, IL, US

Washington, District Of Columbia, US

I represented Abbvie at the R&D Leadership Forum, a group of Heads of R&D and Chief Medical Officers that replaced the Biomedical Advisory Committee (BMAC).

Conshohocken, Pennsylvania, US

As Chief Medical Officer and Head of Development, I represented Abbvie on the Transcelerate Board.

Westlake Village, CA, US

I was also a Founding Partner of Kanan which was established to do focused development on certain cardiovascular targets.

Thousand Oaks, CA, US

During the five years I worked at Amgen, I led the Cardiovascular, Metabolic, Nephrology, Neuroscience, Bone and Inflammation Therapeutic Areas. I also created a Center of Excellence for clinical trial design that utilized a suite of predictive analytic software and RWD to assist teams from all therapeutic areas with rational trial design and execution. As.

Silver Spring, MD, US

FDA's Advisory Committees have industry representatives who act on behalf of regulated industry at committee meetings. The representative discusses an issue before the committee from the perspective of the affected industry and not as an individual from a specific sponsor. Representatives are non-voting members who usually serve a four-year term. Selection.

During my two and a half years at Cerenis, I had the opportunity to live and work in the south of France and experience the working environment in a highly innovative, pre-IPO company of less than thirty people. Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of the next generation HDL therapies..

US

I was Head of Research & Development at AtheroGenics and Executive Vice President. The Heads of Medicinal Chemistry, Biology, Animal Pharmacology, Early Development (including Toxicology and CMC), Clinical Development and Regulatory Affairs reported to me. I managed all aspects of Drug Development from synthesis and screening to Phase IV. The R&D group.

New York, New York, US

As the therapeutic head of the Cardiovascular & Metabolic group, I controlled the clinical and medical marketing support for 40% of the total Pfizer business. There were three Group Leaders reporting to me, Atherosclerosis (Lipitor, Caduet), Diabetes (Glucotrol XL and Exubera) and Cardiovascular (Norvasc, Accupril and Tikosyn). I managed a headcount of.

New Brunswick, NJ, US

At Janssen, I set up and ran clinical programs on anesthetic agents (haloperidol, fentanyl, sufentanyl), anti-infectives (itraconazole), neuroleptics (ritanserin and risperidone), cardiovascular agents (nebivolol, ketanserin), antihelminthics, antihistamines and other agents. I also provided medical support for marketing in those areas where we had.

Mbchb, Medicine

Bsc, Microbiology And Biochemistry